Overview

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatments are medically inadvisable.
Phase:
PHASE2
Details
Lead Sponsor:
Zhejiang Kanova Biopharmaceutical Co., LTD